Scopus BioPharma Inc. Common Stock
SCPS
SCPS was delisted on the 16th of December, 2022.
15 hedge funds and large institutions have $1.07M invested in Scopus BioPharma Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 16 closing their positions.
46% less funds holding
Funds holding: 28 → 15 (-13)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
78% less capital invested
Capital invested by funds: $4.87M → $1.07M (-$3.8M)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$167K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$114K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$18.8K |
| 5 |
Morgan Stanley
New York
|
+$4.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$778K |
| 2 |
BlackRock
New York
|
-$761K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$440K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$403K |
| 5 |
State Street
Boston,
Massachusetts
|
-$344K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | -$18K | -2,188 | Closed |
|
|
SO
27
STRS Ohio
Columbus,
Ohio
| – | -$10K | -1,300 | Closed |
|
28
Legal & General Group
London,
United Kingdom
| – | -$5K | -541 | Closed |
|
29
Citigroup
New York
| – | -$3.32K | -467 | -100% |
|
|
AIP
30
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$4K | -450 | Closed |
|
31
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | -354 | Closed |
|
SCPS Hedge Fund Activity: Q2 2021 in Review
15 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q2 2021, worth a combined $1.07M — down 78% from $4.87M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SCPS and 3 opened new positions — a net loss of 13 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Ergoteles, opening a new position worth an estimated $167K. The largest seller was Millennium Management, exiting entirely with an estimated $778K sold.
- 15 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q2 2021, down from 28 in Q1 2021.
- Funds reported $1.07M of Scopus BioPharma Inc. Common Stock stock for Q2 2021, down 78% quarter-over-quarter.
- 3 funds opened new Scopus BioPharma Inc. Common Stock positions in Q2 2021 and 16 closed out, a net change of -13 holders.
- The largest Scopus BioPharma Inc. Common Stock buyer in Q2 2021 was Ergoteles, an estimated $167K added.
- The largest Scopus BioPharma Inc. Common Stock seller in Q2 2021 was Millennium Management, an estimated $778K sold.
Based on aggregated 13F filings for Q2 2021.